Defining Drug Remission in Psoriasis: Long-Term Data and Insights
Welcome back to another HCP Live Peer Exchange series. In this episode titled, ‘Evolving Treatment Expectations in Psoriasis,’ the panelists discussed how treatment goals in psoriasis have evolved alongside advances in therapeutic innovation and disease understanding. The expert faculty began by reflecting on the historical limitations of traditional therapies, including topicals, phototherapy, and early systemic agents, which were often insufficient for achieving sustained disease control. In earlier eras, treatment success was defined and accepted by improvement rather than complete clearance of the skin.
In this episode, ‘Redefining Treatment Success in Psoriasis,’ the expert dermatologists explore the remarkable evolution of treatment expectations in psoriasis, moving from modest improvements to ambitious goals of complete skin clearance and sustained remission. The faculty reflect that in earlier treatment paradigms even a 50% improvement in disease severity was considered a meaningful success.
Experts share treat-to-target psoriasis goals, when to switch biologics, and how near-clear skin may reduce arthritis risk.
Ambitious psoriasis remission targets spark clinician debate, urging treatment tweaks to achieve sustained clearance, improve quality of life, and reduce comorbidity risks.
Explore how psoriasis biologics differ—TNF vs IL‑23/IL‑17—why classes matter, and what targeted therapy means for safety and results.
New psoriasis data show durable, rapid skin clearance with modern biologics, spotlighting bimekizumab’s four-year remission and patient-tailored selection.
Explore which psoriasis biologics deliver rapid clearance and durable remission, including IL-17 vs IL-23 insights and key differences within IL-17 inhibitors.
Expert panel weighs IL‑17 vs IL‑23 biologics for psoriasis, highlighting fast onset, durability, and why switching within class may work.
Clinicians unpack dual IL‑17A/F blockade in psoriasis and reveal why long‑term efficacy claims vary without rigorous head‑to‑head data.
IL-17 inhibitors clear psoriasis fast; meta-analyses highlight brodalumab, bimekizumab and ixekizumab, with flexible dosing that builds patient confidence.
Learn how experts tackle psoriasis biologic failures—assess primary vs secondary loss, use topicals, and choose smarter switches for clearer skin.
Experts explain managing psoriasis biologic failures: reassess response, use topicals, and switch smarter to reach near‑clear skin.
